GM-CSF-based cellular vaccines: A review of the clinical experience

Cytokine and Growth Factor Reviews

Volumn 13, Issue 2, 2002, Pages 185-193

  Borrello, Ivan ^a   Pardoll, Drew ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; GM CSF; Immunotherapy; Vaccines

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL MODEL; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL MIGRATION; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ERYTHEMA; FATIGUE; FEVER; GENETIC ENGINEERING; HISTOPATHOLOGY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NONHUMAN; PAIN; PRURITUS; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; REVIEW;

CANCER VACCINES; CLINICAL TRIALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 0036005892     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00034-X     Document Type: Short Survey

References (50)

1. Bacteria and cancer - Antagonisms and benefits
2. Viral oncolysis. Increased immunogenicity of host cell antigen associated with influenza virus
3. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells
4. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
5. Multiple tumor-specific antigens expressed on a single tumor cell
6. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2
7. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
8. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
9. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model
10. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
11. T-cell tolerance by clonal anergy in transgenic mice with non-lymphoid expression of MHC class II I-E
12. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
13. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens
14. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
15. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens
16. Flt3 ligand induces tumor regression and anti-tumor immune responses in vivo
17. The Yin and Yang of T cell costimulation
18. Human tumor antigens recognized by T cells
19. Cyclins and cancer
20. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
21. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy
22. Viruses and cancer
23. Universal hepatitis B vaccination in Taiwan
24. Tolerance, danger, and the extended family
25. Paracrine cytokine adjuvants in cancer immunotherapy
26. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage-colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
27. Dendritic cells and the control of immunity
28. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte macrophage-colony stimulating factor
29. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines
30. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte macrophage-colony stimulating factor gene transfer
31. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte macrophage-colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma
32. Demonstration of a rational strategy for human prostate cancer gene therapy
33. Long-term results of a prospective surgical trial comparing 2 cm vs 4 cm excision margins for 740 patients with 1-4 mm melanomas
34. Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells
35. Peptide-induced antiviral protection by cytotoxic T cells
36. Novel allogeneic granulocyte macrophage-colony stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
37. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
38. A universal granulocyte macrophage-colony stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines
39. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent anti-tumor immunity
40. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression
41. Lentiviral vectors for efficient delivery of CD80 and granulocyte macrophage-colony stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses
42. Combination of CD80 and granulocyte macrophage-colony stimulating factor coexpression by a leukemia cell vaccine: Preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia
43. Dendritic cells infiltrating tumors cotransduced with granulocyte macrophage-colony stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
44. Interleukin-12: A cytokine produced by antigenpresenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
45. Enhanced adjuvant effect of granulocyte macrophage-colony stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity
46. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes
47. Chemotherapy: Friend or foe to cancer vaccines?
48. Effects of anticancer drugs on the immune system in humans
49. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines
50. Sustaining the graft-versus-tumor effect through post-transplant immunization with granulocyte macrophage-colony stimulating factor (GM-CSF)-producing tumor vaccines